Inside Takeda’s Plasma-Derived Therapy Ecosystem
Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
Method to measure blood-brain barrier permeability accurately developed
For decades, scientists across the globe have investigated methods to accurately measure drug permeability across the ...
High levels of adrenomedullin found to promote obesity-associated insulin resistance
Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Caris Life Sciences Publishes Landmark Study Demonstrating the Superiority of Caris Assure™
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...
Revitalize and repair with regenerative medicine
Revitalize Orthobiologics and Wellness in Canfield is a full-service restorative medicine and wellness center that offers services like joint injections, weight-loss management, massage therapy, IV ...
Pharmabiz12h
CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4
CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
openheart.bmj5h
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...